Status:

RECRUITING

DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction Solution

Lead Sponsor:

Nottingham University Hospitals NHS Trust

Collaborating Sponsors:

Optellum Ltd.

Conditions:

AI (Artificial Intelligence)

Pulmonary Nodule, Solitary

Eligibility:

All Genders

35+ years

Brief Summary

This study is a multi-centre prospective observational cohort study recruiting patients with 5-30mm solid and part-solid pulmonary nodules that have been detected on CT chest scans performed as part o...

Eligibility Criteria

Inclusion

  • Patients are eligible for the study if all of the following apply:
  • Are aged 35 years or above
  • Have baseline CT study with at least one incidentally detected solid or part-solid (must have a solid component \>=80%) pulmonary nodule that:
  • is not fully calcified
  • Is 5-30mm inclusive in maximum axial diameter for the whole lesion measured using manual electronic callipers
  • Have baseline CT study that includes at least one series that meets all of the following (training for this will be provided):
  • Is of a type that meets VNC instructions for use
  • Comprises at least one full-inspiration breath-hold scans without a high degree of contrast media and does not exhibit quality issues (e.g., motion artefacts)

Exclusion

  • Patients will be excluded from the study if any of the following apply:
  • Have received a diagnosis for cancer in the last 5 years
  • Have thoracic implants that impact the image appearance of the nodule
  • Have more than five reported pulmonary nodules of any size or type excluding fully calcified nodules (this criterion is used as a proxy due to the risk of being an infection or metastasis)
  • Have one or more additional nodules where any of the following applies:
  • Are already undergoing follow-up according to pulmonary nodule management standard care
  • Pure ground glass opacity (GGO) of \>=5mm in maximum axial diameter for the whole lesion measured using manual electronic callipers
  • \>30mm in maximum axial diameter for the whole lesion measured using manual electronic callipers

Key Trial Info

Start Date :

March 23 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

August 1 2025

Estimated Enrollment :

2000 Patients enrolled

Trial Details

Trial ID

NCT05389774

Start Date

March 23 2023

End Date

August 1 2025

Last Update

April 8 2025

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

Betsi Cadwaladr University Health Board

Bangor, United Kingdom

2

Frimley Health NHS Foundation Trust (Wexham Park Hospital)

Frimley, United Kingdom

3

Leeds Teaching Hospitals NHS Trust

Leeds, United Kingdom

4

King's College Hospital NHS Foundation Trust

London, United Kingdom